Dosages for treatment with anti-ErbB2 antibodies

CAFC
  • US 7,371,379 B2
  • Filed: 06/20/2003
  • Issued: 05/13/2008
  • Est. Priority Date: 08/27/1999
  • Status: Active Grant
First Claim
Patent Images

1. A method for the treatment of a human patient diagnosed with cancer characterized by overexpression of ErbB2 receptor, comprising administering an effective amount of an anti-ErbB2 antibody to the human patient, the method comprising:

  • administering to the patient an initial dose of at least approximately 5 mg/kg of the anti-ErbB2 antibody; and

    administering to the patient a plurality of subsequent doses of the antibody in an amount that is approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least two weeks; and

    further comprising administering an effective amount of a chemotherapeutic agent to the patient.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×